#USA #Denver #Cleerly #Heart Disease #Insight Partners

Cleerly Secures Major Funding to Innovate Heart Disease Care

In a landmark development for cardiac health, Cleerly has finalized a substantial funding round, raising a remarkable $106 million to further its mission of transforming heart disease management. The funding, part of a Series C extension round, was led by global software investment firm Insight Partners, alongside Battery Ventures and existing investors. This financial boost is poised to bolster Cleerly’s growth and support its ongoing efforts in clinical evidence generation, ultimately enhancing patient outcomes throughout the coronary care pathway.

Cleerly, recognized as a trailblazer in advanced cardiovascular imaging, aims to redefine the standard of heart disease care. The company’s innovative approach is underpinned by artificial intelligence, utilizing FDA-cleared solutions that facilitate comprehensive analysis of coronary artery disease. Their advanced non-invasive computed tomography (CT) imaging technology allows for detailed phenotyping of heart conditions, made possible by insights drawn from millions of medical images.

Dr. James K. Min, the Founder and CEO of Cleerly, expressed his excitement regarding this significant investment, highlighting its potential to amplify Cleerly’s commercial reach. He noted the importance of this funding, especially in light of recent achievements that include gaining Medicare coverage and receiving a CPT Category I code for advanced plaque analysis. Dr. Min voiced his commitment to making advanced cardiac care accessible to a broader patient base, passionately working towards a future with reduced heart attack incidences.

Insight Partners’ Managing Director, Scott Barclay, elaborated on the investment, emphasizing the value of Cleerly in the realm of cardiac diagnostics. He stated, “Cleerly's pioneering approach to advanced cardiovascular imaging is elevating the field of diagnostic tools for coronary artery disease. This technology is vital and ready to combat the stark realities of heart disease, which remains the leading cause of death worldwide.”

Barclay further emphasized the financial burden cardiovascular diseases impose, costing the nation a staggering $422 billion annually, underscoring the critical need for innovative solutions like Cleerly's.

Cleerly's advanced software enables healthcare professionals to assess plaque burden non-invasively—akin to how mammograms and colonoscopies provide early detection for breast and colorectal cancers. This transformative capability not only enhances diagnostics but is also a crucial tool in the pursuit of preventive cardiology.

In its quest to set a new standard for heart disease management, Cleerly continues to innovate, driven by a world-class team of clinical and technical experts. By enhancing health literacy among all stakeholders involved in coronary care, Cleerly is committed to advancing patient care and, ultimately, eliminating heart attacks.

For comprehensive insights into Cleerly’s pioneering solutions, visit www.cleerlyhealth.com.

As Cleerly embarks on this ambitious journey, it stands as a beacon of hope for patients and healthcare providers alike, promising to reshape the landscape of cardiac care through cutting-edge technology and unwavering dedication.